Incidence and management of cutaneous toxicities associated with cetuximab

Bibliography

• WONG SF: Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin. Ther. (2005) 27(6):684-694.
   PubMed Web of Science ®Google Scholar
• MENDELSOHN J: Blockade of receptors for growth factors: an anticancer therapy – the fourth annual Joseph H. Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin. Cancer Res. (2000) 6:747-753.
   PubMed Web of Science ®Google Scholar
• BASELGA J, NORTON L, MASUI H: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Nod. Cancer Inst. (1993) 85:1327-1333.
   PubMed Web of Science ®Google Scholar
• SALTZ LB, MEROPOL NJ, LOEHRER PJ Sr et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. (2004) 22:1201-1208.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351(4):337-345.
   PubMed Web of Science ®Google Scholar
• BONNER JA, HARARI PM, GIRALT J et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. (2006) 354(6):567-578.
   PubMed Web of Science ®Google Scholar
• TRIGO J, HITT R, KORALEWSKI P et al.: Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a Phase II study. Proc. Am. Soc. Clin. Oncol. (2004):A5502.
   Google Scholar
• SCHRAG D, CHUNG KY, FLOMBAUM C, SALTZ L: Cetuximab therapy and symptomatic hypomagnesemia. J. Natl. Cancer Inst. (2005) 97:1221-1224.
   PubMed Web of Science ®Google Scholar
• BASELGA J, PFISTER D, COOPER MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. (2000) 18:904-914.
   PubMed Web of Science ®Google Scholar
• ROBERT F, EZEKIEL M, SPENCER SA et al.: Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. (2001) 19:3234-3243.
   PubMed Web of Science ®Google Scholar
• BASELGA J, RISCHIN D, RANSON M et al.: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD-1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. (2002) 20:4292-4302.
   PubMed Web of Science ®Google Scholar
• VAN DOORN R, KIRTSCHIG G, SCHEFFER E, STOOF TJ, GIACCONE G: Follicular and epidermal alterations in patients treated with ZD-1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br. J. Dermatol. (2002) 147:598-601.
   PubMed Web of Science ®Google Scholar
• HIDALGO M, SIU LL, NEMUNAITIS J et al.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. (2001) 19:3267-3279.
   PubMed Web of Science ®Google Scholar
• HERBST RS, LORUSSO PM, PURDOM M, WARD D: Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin. Lung Cancer (2003) 4:366-369.
   PubMedGoogle Scholar
• PURDOM M: Management of acneiform rashes related to gefitinib therapy. Clin. J. Oncol. Nurs. (2004) 8:316-317.
   PubMedGoogle Scholar
• LAUX I, JAIN A, SINGH S, AGUS DB: Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br. J. Cancer (2006) 94(1):85-92.
   PubMed Web of Science ®Google Scholar
• ALBANELL J, ROJO F, AVERBUCH S et al.: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD-1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. (2002) 20:110-124.
   PubMed Web of Science ®Google Scholar
• SALTZ L, KIES M, ABBRUZZESE JL et al.: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol. (2003):A204.
   Google Scholar
• TEJPAR S, PEETERS M, HUMBLET Y et al.: Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data. Proc. Am. Soc. Clin. Oncol. (2006):A3554.
   Google Scholar
• VAN CUTSEM E, MAYER RJ, GOLD P et al.: Correlation of acne rash and tumour response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Eur. J. Cancer (2004) 85(Suppl. 2):Abstract 279.
   Google Scholar
• SIPPLES R: Common side effects of anti-EGFR therapy: acneform rash. Semin. Oncol. Nurs. (2006) 22(1 Suppl. 1):28-34.
   PubMedGoogle Scholar
• PÉREZ-SOLER R, DELORD JP, HALPERN A et al.: HER1/EGFR inhibitor-associated rash future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist (2005) 10:345-356.
   PubMed Web of Science ®Google Scholar
• JACOT W, BESSIS D, JORDA E et al.: Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br. J. Dermatol. (2004) 151:238-241.
   PubMed Web of Science ®Google Scholar
• SHAH NT, KRIS MG, PAO W et al.: Practical management of patients with non-small-cell lung cancer treated with gefitinib. J. Clin. Oncol. (2005) 23:165-174.
   PubMed Web of Science ®Google Scholar
• Erbitux (cetuximab) [package insert]. ImClone Systems Incorporated, New York, NY, and Bristol-Myers Squibb Company, Princeton, NJ, USA (2005).
   Google Scholar
• MOSS JE, BURTNESS B: Cetuximab-associated acneiform eruption. N. Engl. J. Med. (2005) 19(e17):353.
   Google Scholar
• RHEE J, OISHI K, GAREY J, KIM E: Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. Clin. Colorectal Cancer (2005) 5(Suppl. 2):S101-S106.
   PubMedGoogle Scholar
• SAPADIN AN, FLEISCHMAJER R: Tetracyclines: nonantibiotic properties and their clinical implications. J. Am. Acad. Dermatol. (2006) 54(2):258-265.
   PubMed Web of Science ®Google Scholar
• SHAPIRO LE, KNOWLES SR, SHEAR NH: Comparative safety of tetracycline, minocycline, and doxycycline. Arch. Dermatol. (1997) 133:12240-12230.
   Google Scholar
• BUSAM KJ, CAPODIECI P, MOTZER R et al.: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br. J. Dermatol. (2001) 144:1169-1176.
   PubMed Web of Science ®Google Scholar
• SEGAERT S, TABERNERO J, CHOSIDOW O et al.: The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J. Dtsch Dermatol. Ges. (2005) 3(8):599-606.
   PubMedGoogle Scholar
• PEREZ-SOLER R, SALTZ L: Cutaneous adverse effects with HER1/EGFR-targeted agents:is there a silver lining? J. Clin. Oncol. (2005) 23(22):5235-5246.
   PubMed Web of Science ®Google Scholar